For: | Li N, Zhu QX, Li GZ, Wang T, Zhou H. Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1α and inhibiting the RhoA/ROCK pathway. World J Diabetes 2023; 14(12): 1862-1876 [PMID: 38222788 DOI: 10.4239/wjd.v14.i12.1862] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v14/i12/1862.htm |
Number | Citing Articles |
1 |
Ke-Xin Zhang, Cheng-Xia Kan, Fang Han, Jing-Wen Zhang, Xiao-Dong Sun. Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control. World Journal of Diabetes 2024; 15(2): 137-141 doi: 10.4239/wjd.v15.i2.137
Abstract(194) |
Core Tip(159) |
Full Article(HTML)(878)
|
Full Article with Cover (PDF)-996K(42)
|
Full Article (Word)-280K(16)
|
Audio-7845K(0)
|
Peer-Review Report-194K(44)
|
Answering Reviewers-179K(26)
|
Full Article (PDF)-656K(143)
|
Full Article (XML)-80K(66)
|
Times Cited (0)
|
Total Visits (2243)
|
Open
|
2 |
Mina Y. George, Mohamed S. Dabour, Eman Rashad, Beshay N. Zordoky. Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy. Antioxidants 2024; 13(6): 671 doi: 10.3390/antiox13060671
|